Latest News and Press Releases

-- MRT5005 is the first clinical-stage mRNA therapeutic with nebulized delivery to the lung and first to be administered in multiple doses for the treatment of a chronic genetic disease -- --...

-- Lead candidate MRT5005 leverages Translate Bio’s proprietary LNP and mRNA platform and is the only clinical-stage mRNA therapeutic in development for the treatment of CF -- -- Second CF program,...

LEXINGTON, Mass., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...

LEXINGTON, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...

-- Pursuing development of mRNA vaccine against COVID-19 through expanded collaboration with Sanofi Pasteur -- -- Existing large-scale manufacturing capacity expected to help meet needs of...

-- FDA grants Rare Pediatric Disease designation for MRT5005 for treatment of cystic fibrosis –  -- Response to COVID-19 pandemic anticipated to cause interruptions in certain clinical trial...

Mit 396 neuen Wägen steigt die Zahl MOVIA Fahrzeuge in Singapur auf 672, wodurch diese U-Bahn-Flotte eine der größten von Bombardier weltweit wirdU-Bahn-Wägen decken eine Gesamtstrecke von 102 km und...

Nouvelle commande de 396 voitures de métro portant le nombre de véhicules MOVIA à Singapour à 672, ce qui en fait l'une des plus grandes flottes de métro de Bombardier au mondeLes deux lignes Mass...

New order of 396 metro cars bring the number of MOVIA vehicles in Singapore to 672, making it one of Bombardier’s largest metro fleet in the world The two high-capacity Mass Rapid Transit (MRT) lines...